Código QR (código de barras bidimensional)

Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer

Abstract Background In 2022, the American Food and Drug Administration and the European Medicines Agency approved [177Lu]Lu-PSMA-617 (PLUVICTO™, Novartis AG, Basel, Switzerland) for radionuclide therapy with prostate-specific membrane antigen (PSMA) ligands in metastatic prostate cancer. Theranostic...

Fuld beskrivelse

Na minha lista:
Principais autores: Jan Heilinger, Jasmin Weindler, Katrin Sabine Roth, Philipp Krapf, Klaus Schomäcker, Markus Dietlein, Alexander Drzezga, Carsten Kobe
Format: Artigo
Sprog:Inglês
Udgivet: SpringerOpen 2023-09-01
Serier:EJNMMI Research
Fag:
Prostate cancer
PSMA
PET
Radionuclide therapy
Theranostics
Quantification
Online adgang:https://doi.org/10.1186/s13550-023-01033-x
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker